 The FDA has granted Breakthrough Therapy designation to Verastem Inc NASDAQ: VSTM for the combination of its investigational VS-6766, with defactinib, for recurrent low-grade serous ovarian cancer LGSOC regardless of KRAS status after one or more prior lines of therapy, including platinum-based chemotherapy. The combination is being evaluated in the Phase 12 FRAME trial. 